Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

BACKGROUND: Inhibition of AKT with MK-2206 has demonstrated synergism with anticancer agents. This phase 1 study assessed the MTD, DLTs, PK, and efficacy of MK-2206 in combination with cytotoxic and targeted therapies. METHODS: Advanced solid tumor patients received oral MK-2206 45 or 60 mg (QOD) wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Molife, L Rhoda, Yan, Li, Vitfell-Rasmussen, Joanna, Zernhelt, Adriane M, Sullivan, Daniel M, Cassier, Philippe A, Chen, Eric, Biondo, Andrea, Tetteh, Ernestina, Siu, Lillian L, Patnaik, Amita, Papadopoulos, Kyriakos P, de Bono, Johann S, Tolcher, Anthony W, Minton, Susan
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2014
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3884022/
https://ncbi.nlm.nih.gov/pubmed/24387695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-7-1
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge